Key facts
- Optieum Biotechnologies’s last known valuation is $8.4M (Mar 2022).
- It has raised $11.4M; the latest was Later Stage VC ($8.5M) in Jan 2025.
- Notable investors include ANRI, UntroD, Keio Innovation Initiative, Iyogin Capital, J-Startup West — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Optieum Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Optieum Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Optieum Biotechnologies
Developer of antibody-based therapies designed to help in the treatment of patients with cancers. The company's therapies facilitate the development and detection of single-chain variable CAR-T cells with enhanced proliferation capacity and longevity, enabling patients to have superior reactivity against advanced tumors and minimize adverse effects.
- Sector
- Healthcare
- HQ
- Toon, Japan
- Founded
- 2020
- Employees
- 9
- Website
- optieumbio.com/
- Ownership
- Privately Held (backing)
Optieum Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Optieum Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Optieum Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.